Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.40 |
| ▸ | KDM1A | O60341 | 3/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14360193 | 0.81 | L3MBTL1 (0.44) | GPR119JAK2JAK1STS | |
| SCHEMBL1310138 | 0.81 | MMP13 (0.39) | KDM4EPKMGPR119KDM1ANR1H2 | |
| SCHEMBL1311007 | 0.81 | MC4R (0.42) | GPR119KDM1A | |
| SCHEMBL1311605 | 0.76 | GRIN2B (0.44) | GPR119KDM1ARORC | |
| SCHEMBL12175567 | 0.73 | APP (0.43) | GPR119KDM1A | |
| SCHEMBL30988946 | 0.71 | KDM4E (0.55) | KDM4EPKMGPR119TGFBR1STS | |
| SCHEMBL25412389 | 0.70 | GPR119 (0.42) | KDM4EPKMGPR119KDM1ATGFBR1 | |
| SCHEMBL31559388 | 0.70 | STS (0.41) | GPR119TGFBR1STSKMT2A | |
| SCHEMBL18115781 | 0.70 | OPRD1 (0.46) | JAK2JAK1STSRORC | |
| SCHEMBL1812162 | 0.70 | CYP11B2 (0.46) | GPR119KDM1ARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981952-B2 | Oxazetidine derivatives, process for preparing them and use in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-05-29 | — | — | US | disclosed |
| EP-2726478-B1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2017-01-11 | — | — | EP | disclosed |
| US-20160237065-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-08-18 | — | — | US | disclosed |
| US-9353083-B2 | Oxazetidine derivatives, process for preparing them and use in human medicine and in cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-05-31 | — | — | US | disclosed |
| US-20140228342-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2014-08-14 | — | — | US | disclosed |
| EP-2726478-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2014-05-07 | — | — | EP | disclosed |
| WO-2013001030-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237065-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS | MC1R, MCHR1, MCHR2 | KDM4E 510/4885PKM 1546/4885GPR119 42/4885 |
| US-20140228342-A1 | OXAZETIDINE DERIVATIVES, PROCESS FOR PREPARING THEM AND USE IN HUMAN MEDICINE AND IN COSMETICS | MC1R, MCHR1, MCHR2 | KDM4E 596/4885PKM 1502/4885GPR119 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.